| Dr Joseph S Spindler, MD | |
|
6655 Travis St, Suite 960, Houston, TX 77030-1312 | |
| (713) 524-4494 | |
| (713) 524-9333 |
| Full Name | Dr Joseph S Spindler |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 52 Years |
| Location | 6655 Travis St, Houston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023010584 | NPI | - | NPPES |
| 082158901 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | E8183 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christus Southeast Texas- St Elizabeth | Beaumont, TX | Hospital |
| Entity Name | Arthritis Clinic Of Houston Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194919837 PECOS PAC ID: 4587839444 Enrollment ID: O20111205000909 |
News Archive
The growing premature birth rate in the United States appears to be strongly associated with increased use of pesticides and nitrates, according to work conducted by Paul Winchester, M.D., professor of clinical pediatrics at the Indiana University School of Medicine.
An experimental drug that acts in a novel way to lower cholesterol proved even more effective than statins and had few undesirable side effects, newly released data shows. The drug acts by modifying the way cholesterol levels are naturally controlled. A protein produced in the liver helps limit the amount of LDL, or "bad" cholesterol, that liver cells can remove from the bloodstream. The new drug, called REGN727, is a monoclonal antibody, made in a laboratory, that blocks the action of that protein.
Optivia Biotechnology, a leading provider of in vitro transporter assay services, today announced that the company and the U.S. Food and Drug Administration have signed a collaboration agreement to assess the effect of dietary supplements on key drug transporters.
Parion Sciences today announced it has received a $3 million award from Cystic Fibrosis Foundation Therapeutics to support the development of P-1037, Parion's new investigational treatment for cystic fibrosis (CF).
OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph S Spindler, MD 6655 Travis St, Suite 960, Houston, TX 77030-1312 Ph: (713) 524-4494 | Dr Joseph S Spindler, MD 6655 Travis St, Suite 960, Houston, TX 77030-1312 Ph: (713) 524-4494 |
News Archive
The growing premature birth rate in the United States appears to be strongly associated with increased use of pesticides and nitrates, according to work conducted by Paul Winchester, M.D., professor of clinical pediatrics at the Indiana University School of Medicine.
An experimental drug that acts in a novel way to lower cholesterol proved even more effective than statins and had few undesirable side effects, newly released data shows. The drug acts by modifying the way cholesterol levels are naturally controlled. A protein produced in the liver helps limit the amount of LDL, or "bad" cholesterol, that liver cells can remove from the bloodstream. The new drug, called REGN727, is a monoclonal antibody, made in a laboratory, that blocks the action of that protein.
Optivia Biotechnology, a leading provider of in vitro transporter assay services, today announced that the company and the U.S. Food and Drug Administration have signed a collaboration agreement to assess the effect of dietary supplements on key drug transporters.
Parion Sciences today announced it has received a $3 million award from Cystic Fibrosis Foundation Therapeutics to support the development of P-1037, Parion's new investigational treatment for cystic fibrosis (CF).
OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.
› Verified 3 days ago
Dr. Michaela Elizabeth Ginn, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 13214 Indian Creek Road, Houston, TX 77079 Phone: 713-591-3555 Fax: 661-321-3286 | |
Ameena Bagree Malhotra, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, 77030-4009, Houston, TX 77030 Phone: 713-792-6161 | |
Svetang Vijay Desai, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 444 Fm 1959 Rd, Suite A, Houston, TX 77034 Phone: 281-481-9400 | |
Dr. Stalin R Subramanian, M.D Rheumatology Medicare: Medicare Enrolled Practice Location: 7200 Cambridge St Fl 8, Houston, TX 77030 Phone: 713-798-0950 | |
Robin Boliver-campbell, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 7141 Southwest Fwy, Houston, TX 77074 Phone: 713-771-7921 Fax: 713-264-8659 | |
Henna Mukhtar Malik, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 13215 Dotson Rd Ste 300, Houston, TX 77070 Phone: 281-894-8822 | |
Zaven Sargsyan, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2002 Holcombe Blvd, Department Of Medicine, Houston, TX 77030 Phone: 713-791-1414 |